Orforglipron for renal insufficiency, chronic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Apr 2023: Trial started, NCT05803421
  2. 7 Apr 2023: Trial registered, NCT05803421

The trials

NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

State
Completed
Phase
Phase 3
People
2,749 taking part
Started
3 Apr 2023
Primary completion
16 Mar 2026
Arms
Orforglipron
Results
None posted
  1. 3 Apr 2023: Trial started
  2. 7 Apr 2023: Trial registered
  3. 16 Mar 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.